 They are proved to be a remarkable marker of the prognosis of early-stage-node negative breast cancer.Importantly, a recent research pointed out cyclin E overexpression is a mechanism of Trastuzumab resistance in HER2+ breast cancer patients.Thus, co-treatment of trastuzumab with CDK2 inhibitors may be a valid strategy.